A discovery from Australian researchers could lead to better treatment for children with neuroblastoma, a cancer that currently claims 9 out of 10 young patients who experience recurrence. The team at the Garvan Institute of Medical Research in Sydney, Australia, found a drug combination that can bypass the cellular defenses these tumors develop that lead to relapse. Read more: https://medicalxpress.com/news/2025-11-drug-combination-sidesteps-resistance-aggressive.html

Despite major therapeutic advances, survival rates remain lower for children from socioeconomically disadvantaged families, a pattern long observed and poorly understood at the biological level. Read more: https://medicalxpress.com/news/2025-11-food-insecurity-linked-tumor-growth.html

When the researchers increased the amount of HIF2α in neuroblastoma cells with many copies of the MYCN gene, they observed a significant reduction in MYCN protein levels. Read more: https://medicalxpress.com/news/2025-10-higher-hif2-aggressive-childhood-cancer.html

First late effects study since new treatments were introduced found high prevalence of hearing loss, growth failure, underweight and lung disease. Read more: https://www.eurekalert.org/news-releases/1102637

A research team from the University of Zurich and the University Children's Hospital Zurich has developed a new approach for treating children with malignant tumors of the nervous system. By combining an approved drug with a specialized diet, they were able to slow down tumor growth and stimulate cancer cells to mature into normal nerve cells. Read more: https://www.news-medical.net/news/20251021/Researchers-develop-a-new-approach-for-treating-children-with-neuroblastoma.aspx

Children whose mothers lived near farms and fields treated with certain pesticides during pregnancy have a higher risk of a deadly cancer that is most commonly found in infants before their first birthday, according to a new study.  Read more: https://www.thenewlede.org/2025/10/pesticides-child-cancer-california/

The FDA has granted orphan drug designation (ODD) to AMXT 1501 in combination with difluoromethylornithine (Iwilfin; DFMO) for the treatment of patients with neuroblastoma. Read more: https://www.targetedonc.com/view/amxt-1501-and-dfmo-combination-achieve-fda-orphan-drug-designation

"Even though naxitamab appeared to have erased the cancer, Dr. Modak wanted to do everything possible to prevent the high-risk neuroblastoma from returning. He proposed that James receive a pioneering treatment: a cancer vaccine that would train his immune system to continuously be on guard to spot and fight malignant cells." Read more: https://www.mskcc.org/news/cancer-vaccine-could-prevent-neuroblastoma-from-returning-after-antibody-treatment

The study found that restricting the cancer’s access to an essential nutrient called arginine yielded promising results, both when used on its own and when used in combination with standard therapies.  Read more: https://www.ccia.org.au/blog/potential-new-treatment-strategy-for-high-risk-neuroblastoma

Researchers have discovered how circular extra-chromosomal DNA drives relapse in childhood cancers and found a way to target dormant...